Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2019, Vol. 24 ›› Issue (5): 541-545.doi: 10.12092/j.issn.1009-2501.2019.05.010

Previous Articles     Next Articles

miR-106 b expression in breast cancer tissues and mechanism of enhancing cisplatin sensitivity in breast cancer cells

ZHENG Zhongqiu 1, XIE Bojian 1, CUI Binbin 1, KE Yichen 1, LIN Yi 2   

  1. 1 Taizhou Hospital of Zhejiang Province, Taizhou 317000, Zhejiang, China; 2 Department of Obstetrics and Gynecology, the Third Affiliated Hospital of Wenzhou Medical University, Wenzhou 325200, Zhejiang, China
  • Received:2018-12-24 Revised:2019-04-22 Online:2019-05-26 Published:2019-05-28

Abstract:

AIM: To explore miR-106 b expression in breast cancer tissues and mechanism of enhancing cisplatin sensitivity in breast cancer cells. METHODS: Fifty-eight cases of breast cancer patients diagnosed and treated in our hospital from October 2015 to May 2015 were randomly selected. Breast cancer tissue and paracancer tissue were taken. Cellular DNA was extracted from breast cancer tissues and adjacent tissues, and the expression level of miR-106 b was detected by real-time PCR. MCF-7 cell lines of breast cancer were purchased to construct the high-expression group promoting the expression of mir-106 b and the low-expression group inhibiting the expression of miR-106 b. After 48 h treatment with cisplatin at different concentrations, the inhibition of tumors in vitro and subcutaneous in nude mice was observed. Fluorescence quantitative PCR was used to detect the expression of PTEN/PI3K/AKT signaling pathway related genes.RESULTS:Real-time PCR showed that the relative expression of miR-106 b in breast cancer tissues was higher than that in adjacent tissues (P<0.05). At 20, 30 and 40 μmol/L concentrations, the cell inhibition rates of the control group and the high expression group were significantly higher than those of the low expression group, and the cell inhibition rate of the control group was significantly higher than that of the low expression group (P<0.05). At the concentrations of 20, 30 and 40 μmol/L, the fluorescence intensity at the corresponding concentrations in the control group and the high expression group was lower than that in the low expression group, and the high expression group was significantly lower than the control group (P<0.05). The relative expression of PTEN in the low expression group was significantly lower than that in the control group, while the relative expression of PTEN in the high expression group was significantly higher than that in the control group (P<0.05). The relative expression levels of PI3K and AKT in the low expression group were significantly higher than those in the control group, and the relative expression levels of PI3K and AKT in the high expression group were significantly lower than those in the control group (P<0.05). CONCLUSION: miR-106 b is highly expressed in breast cancer, and the higher the expression, the more sensitive breast cancer cells are to cisplatin chemotherapy.

Key words: miR-106 b, breast cancer, cisplatin, chemotherapy sensitivity

CLC Number: